 |
Partners' Directory |
| Home Search Join the Partnership Login | |
| Contact | General | Specializations in Countries | Contribution to the Global Plan | Declaration |
View this partner's profile
Organization Contact Information | |
| Name: | Ramparva Samajik Shaikshanik Seva Samiti |
| Street 1: | At.Junna Post.Shikara Tq.Mukhed Dist.Nanded |
| Street 2: | |
| City: | Nanded |
| Province: | |
| Post Code: | 431715 |
| Country: | India |
| Phone: | +919272161123 |
| Organization Email: | ramparva@gmail.com |
| Web Site: | |
| Other Online Presence: | |
|
|
||||||||||||||||||||||||||||
General Information | |
| Board Constituency: | Developing Country NGO |
| Is your organization legally registered in your country: | Yes |
| If yes, please enter your registration number: | MH 484 |
| Organization Type - Primary: | Non-Governmental Organization |
| Organization Type - Secondary: | Other Non-Governmental Organization (NGO) |
| Organization Description: | |
| 1.Vision: Realization of “Social Justice and Peace” for the poor and the marginalized children, youth and women through the process of empowerment. 2.Some 2 million new cases of TB yearly, India bears the highest burden of TB globally. It also has among the highest number of MDR-TB cases. 3.Involve all health care providers to increase the reach of TB services. Ensure the rational use of drugs and diagnostics. Provide access information and treatment for TB – women, children, tribal populations, communities living in geographically difficult areas and vulnerable groups, such as people co-infected with TB and HIV. Outcome of the community Level meetings: Awareness generated on TB. Enhanced awareness on TB centres at the nearest locations Increased referrals of TB cases Motivate / Initiate cases on TB treatment Decreased default cases. Reduce myths and misconceptions on TB and its treatment |
|
| Do you know about the UNHLM declaration: | |
Specializations / Areas of Work | |
|
Advocacy Civil Society and Community Engagement Delivery of health services and care Provision of drugs, diagnostics and commodities Research and Development Working on Community, Rights and Gender (CRG) Working on Key Populations related to TB |
Other Organization Information | |
| Total number of staff in your organization: | 11 - 25 |
| Number of full-time staff who are directly involved with TB: | 6 - 10 |
| Number of part-time staff who are directly involved with TB: | 1 - 5 |
| Number of volunteers who are directly involved with TB: | 1 - 5 |
| How did you hear about the Stop TB Partnership: | Internet search |
| If you were informed or referred by another partner of the Stop TB Partnership please tell us who: | |
| Why do you wish join the Stop TB Partnership: | Involvement in Stop TB Working Groups |
| Are you a member of a Stop TB national partnership: | No |
| Are you in contact with your national TB programme: | No |
| Please tell us how your organization is contributing to your country's national TB control plan: | |
| Involve all health care providers to increase the reach of TB services. Ensure the rational use of drugs and diagnostics. Provide access information and treatment for TB – women, children, tribal populations, communities living in geographically difficult areas and vulnerable groups, such as people co-infected with TB and HIV. Outcome of the community Level meetings: Awareness generated on TB. Enhanced awareness on TB centres at the nearest locations Increased referrals of TB cases Motivate / Initiate cases on TB treatment Decreased default cases. Reduce myths and misconceptions on TB and its treatment |
|
Geographical Reach | |
| Which country is your headquarters located in: | India |
| Which countries do you do operate in: (This includes countries you are conducting activities in) |
India |
Contribution | |
| Please tell us how your organization will contribute to the Global Plan to Stop TB by briefly describing its involvement in any of the areas of work listed below: | |
|
TB Care Delivery: Pursue quality DOTS expansion and enhancement, by improving the case finding are cure through an effective patient-centred approach to reach all patients, especially the poor. Address TB-HIV, MDR-TB and other challenges, by scaling up TB-HIV joint activities, DOTS Plus, and other relevant approaches. Contribute to health system strengthening, by collaborating with other health programmes and general services Involve all health care providers, public, nongovernmental and private, by scaling up approaches based on a public-private mix (PPM), to ensure adherence to the International Standards of TB care. Engage people with TB, and affected communities to demand, and contribute to effective care. This will involve scaling-up of community TB care; creating demand thorugh context-specific advocacy, communication and social mobilization. Enable and promote research for the development of new drugs, diagnostic and vaccines. Operational Research will also be needed to improve programme performance. Drug-Resistant TB: Good quality diagnosis. Good quality microscopy allows health workers to see the tubercle bacilli and is essential to identify the infectious patients who need treatment the most. Good quality drugs. An uninterrupted supply of good quality anti-TB drugs must be available. In the RNTCP, a box of medications for the entire treatment is earmarked for every patient registered, ensuring the availability of the full course of treatment the moment the patient is initiated on treatment. Hence in DOTS, the treatment can never interrupt for lack of medicine. Supervised treatment to ensure the right treatment, given in the right way. The RNTCP uses the best anti-TB medications available. But unless treatment is made convenient for patients, it will fail. This is why the heart of the DOTS programme is "directly observed treatment" in which a health worker, or another trained person who is not a family member, watches as the patient swallows the anti-TB medicines in their presence. |
|
Declaration | |
| Declaration of interests: No conflicts of interest were delacred. | |
| Application date: | August 4, 2013 |
| Last updated: | October 1, 2019 |